Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow OCUL by emailGet an email when OCUL pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about OCUL, unsubscribe in one click. Privacy
📣 What OCUL Says Is Next
first quarter of 2028 · “Following these changes, topline SOL-R results are now expected in the first quarter of 2028.”
Company press release, Aug 3, 2026 · SEC filing
1Q 2027 · “The Company plans to provide regulatory updates during its Investor Day on June 17, 2026. · SOL-R (Phase 3, wet AMD) non-inferiority trial remains on track for topline data in 1Q 2027.”
Company press release, May 5, 2026 · SEC filing
first quarter of 2027 · “Along those lines, SOL-R is progressing expeditiously, with topline data on track for the first quarter of 2027, while HELIOS-3 also remains ongoing.”
Company press release, May 5, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full OCUL picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for OCUL and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.